ProCE Banner Activity

How I Use First-Generation vs Second-Generation BTK Inhibitors in CLL and MCL

Clinical Thought
Without comparative data to guide us, how do we decide between recommending ibrutinib or acalabrutinib? Here’s my take on which factors to consider in your patients with CLL or MCL.

Released: April 13, 2018

Expiration: April 12, 2019

No longer available for credit.

Share

Faculty

John C. Byrd

John C. Byrd, MD

D. Warren Brown Chair of Leukemia Research
Professor of Medicine,
Medicinal Chemistry and Veterinary Biosciences
Director, Division of Hematology
Department of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Acerta Pharma AstraZeneca Group

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Faculty Disclosure

Primary Author

John C. Byrd, MD

D. Warren Brown Chair of Leukemia Research
Professor of Medicine,
Medicinal Chemistry and Veterinary Biosciences
Director, Division of Hematology
Department of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio

John C. Byrd, MD, has disclosed that he has received consulting fees from Pharmacyclics and Acerta.